Jordan I, Briese T, Fischer N, Lau J Y, Lipkin W I
Emerging Diseases Laboratory, Departments of Microbiology and Molecular Genetics, Neurology, and Anatomy and Neurobiology, University of California, Irvine, CA 92697-4292, USA.
J Infect Dis. 2000 Oct;182(4):1214-7. doi: 10.1086/315847. Epub 2000 Aug 22.
West Nile virus (WNV) is an emerging mosquito-borne pathogen that was reported for the first time in the Western hemisphere in August 1999, when an encephalitis outbreak in New York City resulted in 62 clinical cases and 7 deaths. WNV, for which no antiviral therapy has been described, was recently recovered from a pool of mosquitoes collected in New York City. In anticipation of the recurrence of WNV during the summer of 2000, an analysis was made of the efficacy of the nucleoside analogue ribavirin, a broad-spectrum antiviral compound with activity against several RNA viruses, for treatment of WNV infection. High doses of ribavirin were found to inhibit WNV replication and cytopathogenicity in human neural cells in vitro.
西尼罗河病毒（WNV）是一种新出现的由蚊子传播的病原体，1999年8月在西半球首次被报道，当时纽约市爆发脑炎，导致62例临床病例和7人死亡。目前尚无针对WNV的抗病毒疗法，最近从纽约市采集的一批蚊子中分离出了WNV。为了预测2000年夏季WNV的再次出现，对核苷类似物利巴韦林（一种对多种RNA病毒有活性的广谱抗病毒化合物）治疗WNV感染的疗效进行了分析。发现高剂量的利巴韦林在体外可抑制人神经细胞中的WNV复制和细胞致病性。
